PharmacyCodes



Zafirlukast en es it fr

Categorie

Zafirlukast Les marques, Zafirlukast Analogs

Zafirlukast Les marques melange

  • No information avaliable

    • Zafirlukast Formule chimique

    C31H33N3O6S

    Zafirlukast RX lien

    http://www.rxlist.com/cgi/generic/zafirlukast.htm

    Zafirlukast FDA fiche

    Zafirlukast FDA

    Zafirlukast msds (fiche de securite des materiaux)

    Zafirlukast MSDS

    Zafirlukast Synthese de reference

    FJ Brown et al., Eur. pat. Appl. 199543; PR Bernstein et al, US Pat.. 4.859.692 (1986, 1989 fois à ICI)

    Zafirlukast Poids moleculaire

    575.676 g/mol

    Zafirlukast Point de fusion

    139 oC

    Zafirlukast H2O Solubilite

    Aucune information disponible

    Zafirlukast Etat

    Solid

    Zafirlukast LogP

    5.787

    Zafirlukast Formes pharmaceutiques

    Tablet

    Zafirlukast Indication

    Pour la prophylaxie et le traitement de l'asthme.

    Zafirlukast Pharmacologie

    Le zafirlukast est un synthétique, antagoniste sélectif des récepteurs des leucotriènes peptide (ARLT) indiqué pour la prophylaxie et le traitement de l'asthme. Les patients souffrant d'asthme ont été trouvés dans une étude à 25 - 100 fois plus sensibles à l'activité des bronchoconstricting LTD4 inhalé que les sujets non asthmatiques. Dans des études in vitro ont démontré que le zafirlukast contrarié l'activité contractile de trois leucotriènes (LTC4, LTD4 et LTE4) dans la conduite des muscles lisses des voies aériennes à partir d'animaux de laboratoire et des humains. Le zafirlukast empêché intradermique LTD4 induite augmente la perméabilité vasculaire cutanée et inhalation inhibée LTD4 induite par l'afflux des éosinophiles dans les poumons des animaux.

    Zafirlukast Absorption

    Rapidement absorbé après administration orale, réduit après un repas riche en gras ou riches en protéines.

    Zafirlukast Toxicite

    Les effets secondaires comprennent l'estomac éruption cutanée et bouleversée.

    Zafirlukast Information pour les patients

    Patients should be told that a rare side effect of ACCOLATE is hepatic dysfunction, and to contact their physician immediately if they experience symptoms of hepatic dysfunction (eg. right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia). Liver failure resulting in liver transplantation and death has occurred in patients taking zafirlukast .

    ACCOLATE is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during symptom-free periods. ACCOLATE is not a bronchodilator and should not be used to treat acute episodes of asthma. Patients receiving ACCOLATE should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician. Women who are breast-feeding should be instructed not to take ACCOLATE. Alternative antiasthma medication should be considered in such patients.

    The bioavailability of ACCOLATE may be decreased when taken with food. Patients should be instructed to take ACCOLATE at least 1 hour before or 2 hours after meals.

    Eosinophilic Conditions: In rare cases, patients on ACCOLATE therapy may present with systemic eosinophilia, eosinophilic pneumonia, or clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic steroid therapy. These events usually, but not always, have been associated with the reduction of oral steroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between ACCOLATE and these underlying conditions has not been established .

    Zafirlukast Organismes affectes

    Les humains et autres mammifères